{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:42:52Z","timestamp":1789350172690,"version":"build-2803163510"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T00:00:00Z","timestamp":1339545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0039163","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T21:11:37Z","timestamp":1339621897000},"page":"e39163","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function"],"prefix":"10.1371","volume":"7","author":[{"given":"Christy M.","family":"Hebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Brendza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisoun","family":"Sulfab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdeleine","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchi","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall W.","family":"Vivian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trenkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Bjornson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2000-9506","article-title":"Epidemiology of hepatitis C: geographic differences and temporal trends.","volume":"20","author":"A Wasley","year":"2000","journal-title":"Semin Liver Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.","volume":"55","author":"I-h Shih","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"MP Manns","year":"2001","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection.","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection.","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"s536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders.","volume":"54","author":"A Lok","year":"2011","journal-title":"Journal of Hepatology"},{"key":"ref10","first-page":"s172","article-title":"Dual, triple, quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN\/RBV for up to 28 days in treatment na\u00efve genotype 1 HCV subjects.","volume":"54","author":"G Foster","year":"2010","journal-title":"Journal of Hepatology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"s484","DOI":"10.1016\/S0168-8278(11)61227-0","article-title":"Characterization of viral resistance mutations in genotype 1 HCV patients receiving combination therapy with a protease inhibitor and polymerase inhibitor with or without ribavirin.","volume":"54","author":"H Mo","year":"2011","journal-title":"Journal of Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"s478","DOI":"10.1016\/S0168-8278(11)61213-0","article-title":"Emergence and persistence of NS5B mutations following combination treatment with tegobuvir (GS-9190) plus standard of care\u2013long-term follow-up from the phase 2b Study GS-US-196-0103.","volume":"54","author":"C Hebner","year":"2011","journal-title":"Journal of Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.","volume":"285","author":"V Lohmann","year":"1999","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/AAC.00289-10","article-title":"Novel HCV Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a.","volume":"54","author":"M Robinson","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"9204","DOI":"10.1128\/JVI.77.17.9204-9210.2003","article-title":"Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells.","volume":"77","author":"Q Zhu","year":"2003","journal-title":"Journal of Virology"},{"key":"ref16","first-page":"S109","article-title":"A novel fluorescence-based protease assay using the endogenous NS3\/4A protease activity present in the total cell lysates of HCV replicon cells Journal of Clinical Virology","volume":"36","author":"H Yang","year":"2006"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1073\/pnas.96.1.127","article-title":"Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.","volume":"96","author":"JP Condreay","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","article-title":"World Intellectual Property Organization International Application: Novel pyridazine compound and use thereof International.","author":"S Bondy","year":"2008"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2007.09.006","article-title":"Imidazo [4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase.","volume":"77","author":"R Vrancken","year":"2008","journal-title":"Antiviral Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1128\/JVI.80.1.149-160.2006","article-title":"A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase.","volume":"80","author":"J Paeshuyse","year":"2006","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs.","volume":"41","author":"BK Park","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref22","article-title":"A Novel Class of Highly Potent Irreversible Hepatitis C Virus (HCV) NS5B Polymerase Inhibitors.","author":"KX Chen","year":"2012"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bmcl.2006.10.002","article-title":"Isothiazoles as active-site inhibitors of HCV NS5B polymerase.","volume":"17","author":"S Yan","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/jm050859x","article-title":"SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.","volume":"49","author":"JP Powers","year":"2006","journal-title":"J Med Chem"},{"key":"ref25","first-page":"749","article-title":"The Protease Inhibitor GS-9256 and Non-Nucleoside Polymerase Inhibitor Tegobuvir Alone, With RBV or Peginterferon plus RBV in Hepatitis C. Hepatology","volume":"55","author":"S Zeuzem","year":"2012"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0039163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:26:19Z","timestamp":1588965979000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0039163"}},"subtitle":[],"editor":[{"given":"Philippe","family":"Gallay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,13]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0039163","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,13]]}}}